Home
Conditions
Hemostatic Disorders

Clinical trial condition

Hemostatic Disorders

Explore clinical trials studying Hemostatic Disorders. Study availability and eligibility vary by location and protocol.

3,080 public trials 582 recruiting studies

Refine in advanced search Browse all conditions

Hemostatic Disorders trial results

Completed

Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies

NCT02160951

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Novartis Investigative Site Nagoya, Aichi-ken, Japan

Novartis Investigative Site Kobe, Hyōgo, Japan

Novartis Investigative Site Kyoto, Japan

Novartis Investigative Site Okayama, Okayama-ken, Japan

View Trial Details

Completed

A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma

NCT01456689

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Novartis Investigative Site Chicago, Illinois, United States

Novartis Investigative Site Ann Arbor, Michigan, United States

Novartis Investigative Site Rochester, Minnesota, United States

Novartis Investigative Site Houston, Texas, United States

View Trial Details

Completed

Bone Marrow Transplant in Treating Patients With Hematologic Cancers

NCT00005797

Conditions: Anemia, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, +52 more
Locations: H. Lee Moffitt Cancer Center and Research Institute at University of South Florida Tampa, Florida, United States

View Trial Details

Completed

Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

NCT00612716

Conditions: Blood Protein Disorders, Burkitt Lymphoma, Cardiovascular Diseases, +47 more
Locations: Masonic Cancer Center, University of Minnesota Minneapolis, Minnesota, United States

View Trial Details

Completed

Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma

NCT01045681

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: CHRU Hôpital Sud Amiens, France

CHRU, Hôpital du Bocage Angers, France

Centre Hospitalier H.Duffaut Avignon, France

Centre Hospitalier de la Cote Basque Bayonne, France

View all 37 locations

View Trial Details

Completed

Id-KLH Vaccine + T Cells in Subjects With Myeloma Undergoing Transplant

NCT01426828

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania, United States

University of Texas, MD Anderson Cancer Center Houston, Texas, United States

View Trial Details

Completed

Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen Receptor

NCT04650724

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: No.3, Qingchun East Road Hangzhou, Zhejiang, China

View Trial Details

Completed

Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's

NCT02371148

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: AO Riuniti Papardo Piemonte Messina, ME, Italy

Centro di Riferimento Oncologico della Basilicata Rionero in Vulture, PZ, Italy

AUSL di Ravenna Ravenna, RA, Italy

A.O. Bianchi - Melacrino - Morelli Reggio Calabria, RC, Italy

View all 23 locations

View Trial Details

Completed

A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma

NCT02831686

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: Memoral Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States

Memorial Sloan Kettering Bergen Montvale, New Jersey, United States

Memorial Sloan Kettering Commack Commack, New York, United States

View Trial Details

Completed

Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

NCT02504359

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +16 more
Locations: Duke University Medical Center Durham, North Carolina, United States

OHSU Knight Cancer Institute Portland, Oregon, United States

View Trial Details

Hemostatic Disorders

Hemostatic Disorders trial results

Related conditions